Glaucoma - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Glaucoma – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global glaucoma market. The report identifies the key trends shaping and driving the global glaucoma market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global glaucoma sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the global glaucoma market. Its scope includes:

• Annualized global glaucoma therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include Calcium agonists, Rho kinase inhibitors and various combination therapies. In addition to this, RNA-interference, Non-Specific Endothelin-A Receptor Blockers and Adenosine HA3-antagonists are also being studied for the possible use in glaucoma patients.
• Analysis of the current and future market competition in the global glaucoma therapeutics market. Key market players covered include Merck and Santen Pharmaceuticals, NicOx and Bausch and Lomb
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with glaucoma.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global glaucoma market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global glaucoma market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 GLAUCOMA: MARKET CHARACTERIZATION

2.1 Overview
2.2 Glaucoma Market Size
2.3 Glaucoma Market Forecast and CAGR
2.4 Drivers and Barriers for the Glaucoma Market
  2.4.1 Drivers of the Glaucoma Market
  2.4.2 Barriers for the Glaucoma Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 GLAUCOMA MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
  3.2.1 Xalatan
  3.2.2 Cosopt
  3.2.3 Alphagan P
  3.2.4 Travatan Z
  3.2.5 Lumigan
3.3 Key Takeaway

4 GLAUCOMA: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Glaucoma Therapeutics – Promising Drugs under Clinical Development.
4.4 Drugs under Clinical Development
  4.4.1 Tafluprost (Saflutan)
  4.4.2 NCX-116 (Formerly PF-03187207)
  4.4.3 Catioprost
4.5 Glaucoma Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Glaucoma Pipeline – Pipeline by Phase of Clinical Development
  4.6.1 Glaucoma Therapeutics – Phase III Clinical Pipeline
  4.6.2 Glaucoma Therapeutics – Phase II Clinical Pipeline
  4.6.3 Glaucoma Therapeutics – Phase I Clinical Pipeline
  4.6.4 Glaucoma Therapeutics – Preclinical Pipeline
  4.6.5 Glaucoma Therapeutics – Discovery Pipeline
4.7 Discontinued / Suspended Drugs for Glaucoma
4.8 Key Takeaway

5 GLAUCOMA MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

6 GLAUCOMA MARKET: FUTURE PLAYERS IN THE GLAUCOMA MARKET

6.1 Introduction
6.2 NicOx SA and Bausch and Lomb
  6.2.1 Overview
  6.2.2 Business Description
  6.2.3 Ophthalmology Portfolio
  6.2.4 Glaucoma Product Portfolio
6.3 Novagali Pharma SA
  6.3.1 Overview
  6.3.2 Business Description
  6.3.3 Glaucoma Product Portfolio
6.4 Merck (MSD) and Santen Pharmaceuticals, Japan
  6.4.1 Overview
  6.4.2 Business Description
  6.4.3 Glaucoma Product Portfolio

7 GLAUCOMA MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

LIST OF TABLES

Table 1: Global Glaucoma Market Revenues, ($bn) 2001-2009
Table 2: Global Glaucoma Market Forecast, ($bn) 2009-2016
Table 3: Strategic Competitor Assessment of the Major Marketed Products in Glaucoma, 2010
Table 4: Major Marketed Products in the Glaucoma Market, 2010
Table 5: Glaucoma Therapeutics –Promising Drugs Under Clinical Development, 2010
Table 6: Glaucoma Therapeutics – Phase III Clinical Pipeline, 2010
Table 7: Glaucoma Therapeutics – Phase II Clinical Pipeline, 2010
Table 8: Glaucoma Therapeutics – Phase I Clinical Pipeline, 2010
Table 9: Glaucoma Therapeutics – Preclinical Pipeline, 2010
Table 10: Glaucoma Therapeutics – Preclinical Pipeline, 2010
Table 11: List of Discontinued Drugs for Glaucoma, 2010
Table 12: NicOx: Glaucoma Pipeline, 2010
Table 13: Novagali Pharma SA –Glaucoma and Ophthalmology Pipeline, 2010
Table 14: Merck and Santen Pharmaceuticals - Ophthalmology Pipeline, 2010
Table 15: Santen Pharmaceuticals - Ophthalmology Pipeline, 2010
Table 16: Santen Pharmaceuticals – Glaucoma Pipeline, 2010

LIST OF FIGURES

Figure 1: Global Glaucoma Market Revenues, ($bn) 2001–2009
Figure 2: Global Glaucoma Market Forecast, ($bn) 2009-2016
Figure 3: Opportunity and Unmet Need in the Glaucoma Market, 2010
Figure 4: Reduction in IOP in Patients Using Either Latanoprost or Cosopt over Three Months
Figure 5: Technology Trends Analytic Framework of the Glaucoma Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of Glaucoma Pipeline – Description, 2010
Figure 7: Glaucoma Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Glaucoma Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Glaucoma Market, 2010
Figure 10: Glaucoma Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology, 2010
Figure 12: GlobalData Market Forecasting Model, 2010

COMPANIES MENTIONED

NicOx SA and Bausch and Lomb
Novagali Pharma SA
Merck (MSD) and Santen Pharmaceuticals, Japan Skip to top